Neil and his study partner Brian have been exceptional participants in clinical research, showing consistent dedication and commitment. Despite initially screen failing due to medical criteria, Neil managed his blood pressure with his primary care provider and qualified for the AD trial.
They have always been accommodating with demanding study schedules and have shown strong support by attending community lectures and advocating for our site. Neil’s determination to follow every protocol detail reflects his deep commitment to advancing treatment for Alzheimer’s disease.